Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR)

Equities research analysts at Canaccord Genuity Group started coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 479.71% from the company’s previous close.

Separately, Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th.

Marker Therapeutics Stock Performance

Shares of NASDAQ:MRKR opened at $1.38 on Wednesday. The firm’s 50 day moving average is $2.22 and its two-hundred day moving average is $2.99. Marker Therapeutics has a 52 week low of $1.35 and a 52 week high of $5.99.

Insiders Place Their Bets

In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the acquisition, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This trade represents a 51.73 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Steve Elms bought 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average price of $3.20 per share, with a total value of $35,472.00. Following the completion of the acquisition, the director now directly owns 325,370 shares of the company’s stock, valued at $1,041,184. This represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Millennium Management LLC bought a new stake in shares of Marker Therapeutics during the 4th quarter worth $50,000. Invst LLC purchased a new stake in shares of Marker Therapeutics during the third quarter valued at $56,000. Northern Trust Corp boosted its position in shares of Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after purchasing an additional 21,703 shares during the period. LPL Financial LLC purchased a new position in Marker Therapeutics in the 4th quarter worth about $248,000. Finally, Aisling Capital Management LP increased its stake in Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after purchasing an additional 11,084 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.